Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and leptomeningeal metastasis

被引：0
|
作者：
Fan, Y. [1 ]
Wu, H. [1 ]
Chen, K. [1 ]
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Leptomeningeal metastases; EGFR TKI resistance; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-30
引用
收藏
页码：S652 / S652
页数：1
相关论文
共 50 条
  • [41] Matched Targeted Therapy by cfDNA of CSF Beyond Leptomeningeal Metastases Progression Upon Osimertinib in EGFR-Mutated NSCLC Patients
    Zheng, M.
    Li, Y.
    Tu, H.
    Sun, H.
    Yin, K.
    Yang, J.
    Zhang, X.
    Zhou, Q.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S877 - S877
  • [42] Modelling long-term survival outcomes in patients with stage (stg) IBeIIIA EGFR-mutated NSCLC from the ADAURA trial
    Cheema, P. K.
    Heeg, B.
    Dyer, M.
    Wu, Y-L.
    John, T.
    Shepherd, F. A.
    de Marinis, F.
    Melosky, B.
    Samson, B.
    Moldaver, D.
    Shaw, S.
    Miranda, M.
    Verhoek, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S936 - S937
  • [43] Treatment adherence and clinical outcomes of osimertinib (Osi) among ethnic-minority patients (pts) with EGFR-mutated NSCLC
    Lee, Matthew
    Miao, Emily
    Zhang, Chenxin
    Xue, Xiaonan
    Tuckman, Steven
    Halmos, Balazs
    Cheng, Haiying
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC
    Lin, Chia-Ying
    Chang, Chao-Chun
    Su, Po-Lan
    Lin, Chien-Chung
    Tseng, Yau-Lin
    Su, Wu-Chou
    Yen, Yi-Ting
    MEDICINE, 2019, 98 (33)
  • [45] Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis
    Li, Shih-Hong
    Hsieh, Meng-Heng
    Fang, Yueh-Fu
    MEDICINE, 2015, 94 (41)
  • [46] Association of different EGFR mutations with different outcomes in EGFR-mutated NSCLC patients treated with tyrosine kinase inhibitors.
    Ulivi, Paola
    Petracci, Elisabetta
    Dazzi, Claudio
    Verlicchi, Alberto
    Canale, Matteo
    Chiadini, Elisa
    Capelli, Laura
    Gamboni, Alessandro
    Papi, Maximilian
    Burgio, Marco Angelo
    Mariotti, Marita
    De Luigi, Nicoletta
    Ludovini, Vienna
    Bennati, Chiara
    Chiari, Rita
    Crino, Lucio
    Amadori, Dino
    Delmonte, Angelo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Osimertinib for Leptomeningeal Disease in EGFR- Mutated NSCLC
    Hegde, Aparna
    Velcheti, Vamsidhar
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (11) : 1705 - 1708
  • [48] Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
    Li, Xingyuan
    Huang, Huayan
    Sun, Yingjia
    Jiang, Qing
    Yu, Yongfeng
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [49] An Effective Treatment for EGFR-mutated Lung Adenocarcinoma with Symptomatic Leptomeningeal Metastases Using Aumolertinib
    Zhang, X.
    Wu, Y.
    Hu, Y.
    Zhang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S415 - S415
  • [50] CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (10): : E516 - E516
12345